Ernexa Therapeutics Inc.

ERNA

NASDAQHealthcareBiotechnology

在 GoAI 中打開

一般交易時段

US$5.1577

+US$0.2977 · +6.13%

8月24日下午2:53 ET

盤中時間採用ET。市場資料可能有所延遲。

GoAI 研究快照

簡明呈現最新可用的模型資訊。

2026年7月10日

25/ 100

GoAI評分

Sell

Trim exposure — unfavorable risk-reward

估值

Expensive

動能

Strong Down

情緒

Mixed

風險韌性

High Risk

完整 GoAI 研究

繼續查看更深入的依據、催化因素和風險。

看完整研究

人工智慧產生的上下文僅供參考，並非投資建議。

公司概況

公司網站

Ernexa Therapeutics Inc. is a biotechnology firm currently in its preclinical development phase, specializing in the creation of therapeutic interventions using induced mesenchymal stem cells (iMSCs). The company's primary focus lies in addressing solid tumor cancers and a range of autoimmune diseases. Its flagship candidate, ERNA-101, is an allogeneic iMSC designed to release pro-inflammatory cytokines, namely IL-7 and IL-15, intended for the treatment of ovarian cancer. Additionally, Ernexa is developing ERNA-102, an iMSC product engineered to secrete the anti-inflammatory cytokine IL-10, aimed at managing rheumatoid arthritis. The company has a licensing arrangement in place with Factor Bioscience Limited. Established in 2018, this Cambridge, Massachusetts-based entity operated as Eterna Therapeutics Inc. until its rebranding to Ernexa Therapeutics in March 2025.

產業: Biotechnology
部門: Healthcare
總部: US
執行長: Sanjeev Luther
上市以來: 1991年8月29日
僱員: 5